Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Acetazolamide Pill · 1 trial · 4 indications
the primary outcome measure is performance of a 2-mile treadmill time trial (self-paced) at simulated altitude.
| Arm | Type | Description |
|---|---|---|
| acetazolamide arm | ACTIVE_COMPARATOR | This is the arm of the study in which the volunteers will take the acetazolamide (Diamox) pill. |
| placebo arm | PLACEBO_COMPARATOR | This is the arm of the study in which volunteers will take the placebo. |
| Name | Type | Description |
|---|---|---|
| Acetazolamide Pill | DRUG | Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude. |
| Placebo pill | DRUG | Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude. |
Inclusion Criteria: Volunteers must meet all of the following criteria to be included in the study: * Male or female, age 18-45 * In good health as determined by Office of Medical Support and Oversight (OMSO) General Medical Clearance * Passed his/her most recent Army Physical Fitness Test (APFT; ...
Acetazolamide Pill is an investigational small molecule being studied for hypoxia, a condition of insufficient oxygen in the body. It is being developed by United Therapeutics Corporation. The drug is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials and is not yet approved for any use.
Acetazolamide Pill is a small molecule being developed for hypoxia. The specific molecular target or target class has not been disclosed in available information. The drug is being studied for its effects on exercise performance, cognitive function, and dexterity under hypoxic conditions.
Acetazolamide Pill is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker UTHR. The company is conducting clinical research on this drug for the treatment of hypoxia.
Acetazolamide Pill is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in early-stage trials to evaluate its safety and effects in healthy volunteers.
Acetazolamide Pill has one completed clinical trial, NCT03525561, titled 'Acetazolamide and Exercise Performance at Altitude'. This early Phase 1 study enrolled 10 participants in the United States and was placebo-controlled, though not double-blinded. The trial investigated hypoxia, exercise performance, cognitive function, and dexterity.
Acetazolamide Pill is a formulation of acetazolamide, a well-known carbonic anhydrase inhibitor. However, the specific brand name or alternative names for this investigational product have not been provided. The drug is being developed by United Therapeutics for hypoxia and is currently in Phase 1 trials.